Table 2.
Combination of HDAC and NF-κB inhibitors against synovial sarcoma cells.
| Timepoint (hrs) | IC50 average | |||
|---|---|---|---|---|
| MS-275 | BAY 11-7085 | Combination (μM) | ||
| (μM) | (μM) | MS-275 | BAY 11 | |
| 24 | 4.5 | 3.5 | 0.45 | 1.4 |
| 48 | 0.56 | 3.4 | 0.27 | 0.8 |
Combination of HDAC and NF-κB inhibitors against synovial sarcoma cells.
| Timepoint (hrs) | IC50 average | |||
|---|---|---|---|---|
| MS-275 | BAY 11-7085 | Combination (μM) | ||
| (μM) | (μM) | MS-275 | BAY 11 | |
| 24 | 4.5 | 3.5 | 0.45 | 1.4 |
| 48 | 0.56 | 3.4 | 0.27 | 0.8 |